Early detection of ovarian tumors using ultrasound

Women's Health

Volumn 9, Issue 1, 2013, Pages 39-57

  Pavlik, Edward J ^a   Van Nagell, John R ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

morphology indexing; ovary; screening; serial transvaginal ultrasound

Indexed keywords

BEVACIZUMAB; CA 125 ANTIGEN;

CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); COST CONTROL; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DRUG COST; EARLY DIAGNOSIS; FOLLOW UP; HEALTH CARE AVAILABILITY; HUMAN; INTERMETHOD COMPARISON; MEDICAL CARE; OVARY CANCER; PREDICTIVE VALUE; PUBLIC HEALTH PROBLEM; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SALPINGOOOPHORECTOMY; SENSITIVITY AND SPECIFICITY; TRANSVAGINAL ECHOGRAPHY;

EID: 84871200802     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.12.62     Document Type: Review

References (53)

1. Pavlik EJ, Saunders BA, Doran S et al. The search for meaning - symptoms and transvaginal sonography screening for ovarian cancer. Cancer 115, 3689-3698 (2009).
2. Rossing MA, Wicklund KG, Cushing- Haugen KL, Weiss NS. Predictive value of symptoms for early detection of ovarian cancer. J. Natl Cancer Inst. 102, 222-229 (2010).
3. Prorok PC. Evaluation of screening program for the early detection of cancer. Natl Cancer Inst. Stat. Textbk Monog. 51, 267-328 (1984).
4. Hulka BS. Cancer screening: degrees of proof and practical application. Cancer 62(Suppl.), 1776-1789 (1988).
5. Downey L, Curtis JR, Lafferty WE, Herting JR, Engelberg RA. The quality of dying and death (QODD) questionnaire. empirical domains and theoretical perspectives. J. Pain Symptom Manag. 39, 9-22 (2010).
6. Cooper AL, Nelson DF, Doran S et al. Long term survival and cost of treatment in patients with Stage IIIC epithelial ovarian cancer. Curr. Women's Health Rev. 5, 44-50 (2009).
7. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 62, 10-29 (2012).
8. Ryerson AB, Eheman C, Burton J et al. Symptoms, diagnoses, and time to key diagnostic procedures among older U.S. women with ovarian cancer. Obstet. Gynecol. 109, 1053-1061 (2007).
9. Campbell S, Bhan V, Royston P, Whitehead MI, Collins WP. Transabdominal ultrasound screening for early ovarian cancer. Br. Med. J. 299, 1363-1367 (1989).
10. Dellenbach P, Nisand I, Moreau L et al. Transvaginal sonographically controlled ovarian follicle puncture for egg retrieval. Lancet 1, 1467-1471 (1984).
11. Schwimer SR, Lebovic J. Transvaginal pelvic ultrasonography. J. Ultrasound Med. 3, 381-383 (1984).
12. Schwimer SR, Lebovic J. TVS pelvic ultrasonography: accuracy in follicle and cyst size determination. J. Ultrasound Med. 4, 61-63 (1985).
13. Jacobs I, Bridges J, Reynolds C et al. Multimodal approach to screening for ovarian cancer. Lancet 331, 268-271 (1988).
14. Higgins RV, van Nagell JR Jr, Donaldson ES et al. Transvaginal sonography as a screening method for ovarian cancer. Gynecol. Oncol. 34, 402-406 (1989).
15. McCluggage WG. The pathology of and controversial aspects of ovarian borderline tumors. Curr. Opin Oncol. 22, 462-472 (2010).
16. Uzan C, Kane A, Rey A et al. How to follow up advanced-stage borderline tumors? Mode of diagnosis of recurrence in a large series stage II-III serous borderline tumors of the ovary. Ann. Oncol. 22, 631-635 (2011).
17. Kurman RJ, Shih I. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am. J. Surg. Pathol. 34, 433-443 (2010).
18. Landen CN, Birrer MJ, Sood A. Early events in the pathogenesis of epithelial ovarian cancer. J. Clin. Oncol. 26, 995-1005 (2008).
19. Kikkawa F, Nawa A, Kajiyama H, Shibata K, Ino K, Nomura S. Clinical characteristics and prognosis of mucinous tumors of the ovary. Gynecol. Oncol. 103, 171-175 (2006).
20. Goodman MT, Shvetsov YB. Incidence of ovarian, peritoneal and fallopian tube carcinomas in the United States, 1995-2004. Cancer Epidemiol. Biomarkers Prev. 18, 132-139 (2009).
21. van Nagell JR, Miller RW, DeSimone CP et al. Long-term survival of women with epithelial ovarian cancer detected by ultrasonographic screening. Obstet. Gynecol. 118, 1212-1221 (2011).
22. Buys SS, Partridge E, Black A et al. Effect of screening on ovarian cancer mortality - the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. J. Am. Med. Assoc. 305, 2295-2303 (2011).
23. Menon U, Gentry-Maharaj A, Hallett R et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 10, 327-340 (2009).
24. Kobayashi H, Yamada Y, Sado T et al. A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int. J. Gynecol. Cancer 18, 414-420 (2008).
25. Partridge E, Kreimer AR, Greenlee RT et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet. Gynecol. 113, 775-782 (2009).
26. Menon U, Gentry-Maharaj A, Jacobs I. Ovarian cancer screening and mortality. J. Am. Med. Assoc. 306, 1544-1545 (2011).
27. Printz C. CancerScope ASCO highlights new findings on cancer screening discoveries connected to ovarian, cervical and prostate cancer. Cancer 117, 3627-3629 (2011).
28. Martzband P, Groopman J. There is more to life than death. N. Engl. J. Med. 367, 987-989 (2012).
29. Crum CP, Mckeon FD, Wian W. The oviduct and ovarian cancer: causality, clinical implications and "targeted prevention." Clin. Obstet. Gynecol. 55, 24-35 (2012).
30. Ueland FR, Depriest P, Desimone C et al. The accuracy of examination under anesthesia and transvaginal sonography in evaluating ovarian size. Gynecol. Oncol. 99, 400-403 (2005).
31. Slomski A. Screening women for ovarian cancer still does more harm than good. J. Am. Med. Assoc. 307, 2474-2475 (2012).
32. Humphrey LL, Hefland M, Chan BKS, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann. Intern. Med. 137, 347-360 (2002).
33. Elmore JG, Armstrong K, Lehman CD, Fletcher SW. Screening for breast cancer. JAMA 293, 1245-1256 (2005).
34. Lehman CD, Gatsonis C, Kuhl CK et al. MRI Evaluation of the contralateral breast in women with recently diagnosed breast cancer. N. Engl. J. Med. 356, 1295-1303 (2007).
35. Bennett RL, Blanks RG. Should a standard be defined for the positive predictive value (PPV) of recall in the UK NHS Breast Screening Programme? Breast 16, 55-59 (2007).
36. Kopans DB. The positive predictive value of mammography. Am. J. Roentgenol. 158, 521-526 (1992).
37. Venkatesan A, Philip P, Kerlikowske K, Sickles EA, Smith-Bindman R. Positive predictive value of specific mammographic findings according to reader and patient variables. Radiology 250, 648-657 (2009).
38. Ware Miller R, Smith A, DeSimone CP et al. Performance of the American College of obstetricians and gynecologists' ovarian tumor referral guidelines with a multivariate index assay. Obstet. Gynecol. 117, 1298-1306 (2011).
39. Pavlik EJ, van Nagell JR, DePriest PD et al. Participation in transvaginal ovarian cancer screening: compliance, correlation factors, and costs. Gynecol. Oncol. 57, 395-400 (1995).
40. Pavlik EJ, Johnson TL, DePriest PD, Andrykowski MA, Kryscio RJ, van Nagell Jr. Continuing participation supports ultrasound screening for ovarian cancer. Ultrasound Obstet. Gynecol. 15, 354-364 (2000).
41. Cohn DE, Kim KH, Resnick KE, O'Malley DM, Straughn JM. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J. Clin. Oncol. 29, 1247-1251 (2011).
42. Yabroff KR, Bradley CJ, Mariotto AB, Brown ML, Feuer EJ. Estimates and projections of value of life lost from cancer deaths in the United States. J. Natl Cancer Inst. 100, 1755-1762 (2008).
43. Gentry-Maharaj A, Sharma A, Burnell M et al. Volunteer acceptance of transvaginal scanning - United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) experience. Ultrasound Obstet. Gynecol. doi:10.1002/uog. 12262 (2012) (Epub ahead of print).
44. Pavlik EJ, van Nagell Jr. Ovarian cancer screening - what women want. Int. J. Gynecol. Cancer 22(Suppl. 1), S21-S23 (2012).
45. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann. Surg. 240, 205-213 (2004).
46. Salsman JM, Pavlik E, Boerner LM, Andrykowski MA. Clinical, demographic, and psychological characteristics of new, asymptomatic partipants in a transvaginal ultrasound screening program for ovarian cancer. Prev. Med. 39, 315-322 (2004).
47. Lykins EL, Pavlik E, Andrykowski MA. Validity of self-reports of return for routine repeat screening in an ovarian screening program. Cancer Epidemiol. Biomarkers Prev. 16, 490-493 (2007).
48. Gaugler JE, Pavlik E, Salsman JM, Andrykowski MA. Pyschological and behavioral impact of receipt of a "normal" ovarian cancer screening test. Prev. Med. 42, 463-470 (2006).
49. Andrykowski MA, Boerner LM, Salsman JM, Pavlik E. Psychological response to test results in an ovarian cancer screening program: a prospective, longitudinal study. Health Psychol. 23, 622-630 (2004).
50. Ryan PY, Graves KD, Pavlik EJ, Andrykowski MA. Abnormal ovarian cancer screening test result: women's informational, psychological and practical needs. J. Psychosoc. Oncol. 25, 1-18 (2007).
51. Andrykowski MA, Pavlik E. Response to an abnormal ovarian cancer-screening test result: test of the social cognitive processing and cognitive social health information processing models. Psychol. Health 26, 383-397 (2011).
52. Coleman MP, Forman D, Bryant H et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 377, 127-138 (2011).
53. Sahr RC. Consumer Price Index (CPI) Conversion Factors 1774 to estimated 2022 to Convert to Dollars of 2011. Oregon State University, OR, USA (2011). http://oregonstate.edu/cla/polisci/sites/ default/files/faculty-files/sahr/ cv2011.xls